A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
Public ClinicalTrials.gov record NCT04489888. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). No statistical hypothesis will be tested in this study.
Study identification
- NCT ID
- NCT04489888
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2020 (Actual)
- Primary completion
- Feb 20, 2023 (Actual)
- Completion
- Jun 28, 2024 (Actual)
- Last update posted
- Jun 19, 2025
2020 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale-New Haven Hospital-Yale Cancer Center ( Site 0265) | New Haven | Connecticut | 06510 | — |
| Helen F. Graham Cancer Center & Research Institute ( Site 0214) | Newark | Delaware | 19718 | — |
| Baptist MD Anderson Cancer Center ( Site 0215) | Jacksonville | Florida | 32207 | — |
| Orlando Health, Inc. ( Site 0216) | Orlando | Florida | 32806 | — |
| Regions Hospital ( Site 0227) | Saint Paul | Minnesota | 55101 | — |
| Washington University School of Medicine ( Site 0240) | St Louis | Missouri | 63110 | — |
| Erie County Medical Center-Head & Neck Surgery and Plastic & Reconstructive Surgery ( Site 0268) | Buffalo | New York | 14215 | — |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0262) | Mineola | New York | 11501 | — |
| Novant Health Presbyterian ( Site 0261) | Charlotte | North Carolina | 28204 | — |
| Novant Health Forsyth Medical Center ( Site 0266) | Winston-Salem | North Carolina | 27103 | — |
| UPMC Hillman Cancer Center ( Site 0253) | Pittsburgh | Pennsylvania | 15232 | — |
| Abington Hospital - Asplundh Cancer Center ( Site 0229) | Willow Grove | Pennsylvania | 19090 | — |
| Charleston Oncology ( Site 0231) | Charleston | South Carolina | 29414 | — |
| Virginia Commonwealth University ( Site 0233) | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04489888, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2025 · Synced Oct 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04489888 live on ClinicalTrials.gov.